Shares of Nastech Pharmaceutical ( NSTK) sank 6.4% to $13.17 Thursday after the company said it priced a public offering of 3.25 million shares at approximately $13.20 a share.

Novartis' ( NVS) shares sank on preliminary results showing that sales of its eye drug Visudyne, which it co-markets with QLT ( QLTI), fell nearly 29%.

Novartis shares were 2.5% lower to $58.06. QLT's shares were up 4 cents to $8.74 after falling earlier in the day.

Sales of Visudyne as well as OSI Pharmaceuticals' ( OSIP) drug Macugen have taken a hit since the approval of Genentech's ( DNA) eye drug Lucentis in June.

Shares of medical appliance manufacturer Somanetics ( SMTS) plummeted 14.3% to $20.01 after the company announced fourth-quarter revenue that fell short of expectations.

The company earned $5.3 million, or 37 cents a share, in the fourth quarter, including a $3.4 million tax benefit, down from 43 cents a share in the year-ago quarter. While revenue was up 25% to $7.68 million in the quarter, analysts surveyed by Thomson First Call were expecting revenue of $8.94 million.

Shares of Barrier Therapeutics ( BTRX) sank 4.7% to $8.20 after the stock was downgraded to hold from buy by analysts at Roth Capital.

"We prefer to reduce to a Hold rating at this time until further progress is achieved" in the company's research pipeline, wrote analyst Mark Taylor. He maintains a 12-month price target of $9.

If you liked this article you might like

Nationwide Egg Recall Expanded

10 Toy Fads That Have Faded

Boomers Feel Recession Burden, Blame

KFC Franchisees Want 'Fried' to Be the Focus

Heavy Weights: More Expensive, Less Effective